Search results for "Drug-eluting stent"

showing 10 items of 46 documents

Long-term outcome after drug-eluting stents implantation: Target lesion versus nontarget lesion repeated intervention

2010

Abstract We sought to investigate the relative clinical significance of target and nontarget lesions repeated percutaneous coronary intervention (re-PCI) in patients implanted with drug-eluting stents (DES). Out of 2626 consecutive DES patients, we retrospectively selected 166 (6.3%; 123 males, aged 65±10years) who had a clinically-driven re-PCI over a mean follow-up of 15months. Seventy-five patients (45%) underwent the second procedure for disease progression in nontarget lesions (nontarget lesion re-PCI group) while 91 (55%) showed target lesion in-stent restenosis or thrombosis (target lesion re-PCI group), with no significant intergroup difference in the temporal trends of re-PCI. The …

Target lesionmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentPercutaneous coronary interventionmedicine.diseaseSurgeryCoronary artery diseaseLesionAtherectomysurgical procedures operativeRestenosisDrug-eluting stentAngioplastymedicinecardiovascular diseasesRadiologymedicine.symptomCardiology and Cardiovascular MedicinebusinesstherapeuticsInternational Journal of Cardiology
researchProduct

Commentary: Be Innovative, Stay Clinical! Time for a Patient-Specific SFA Treatment Algorithm?

2020

International audience

medicine.medical_specialtyAtherectomyDrug coated balloonmedicine.medical_treatment[SDV]Life Sciences [q-bio]MEDLINEFemoral artery030204 cardiovascular system & hematologyBalloonAtherectomy03 medical and health sciences0302 clinical medicineAngioplastymedicine.arterymedicineHumansRadiology Nuclear Medicine and imaging030212 general & internal medicineComputingMilieux_MISCELLANEOUSbusiness.industryPatient specificSurgeryFemoral ArteryTreatment OutcomeDrug-eluting stentSurgeryCardiology and Cardiovascular MedicinebusinessAlgorithmsAngioplasty Balloon
researchProduct

Drug-Coated Balloon Versus Drug-Eluting Stent for Small Coronary Vessel Disease

2020

Abstract Objectives This study sought to compare the performance of a novel drug-coated balloon (DCB) (Elutax SV, Aachen Resonance, Germany), with an everolimus-eluting stent (EES) (Abbott Vascular...

medicine.medical_specialtyDrug coated balloonbusiness.industrymedicine.medical_treatmentStent030204 cardiovascular system & hematologyBalloonlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawDrug-eluting stentCoronary vesselmedicine030212 general & internal medicineRadiologyCardiology and Cardiovascular MedicinebusinessJACC: Cardiovascular Interventions
researchProduct

Safety and efficacy of biodegradable polymer-coated thin strut sirolimus-eluting stent vs. durable polymer-coated everolimus-eluting stent in patient…

2018

Introduction The biodegradable polymer drug-eluting stents were developed to improve vascular healing. However, further data are needed to confirm the safety and efficacy of these stents in patients with acute myocardial infarction (AMI). Aim We sought to determine the 1-year clinical follow-up in patients with AMI treated with a thin strut biodegradable polymer-coated sirolimus-eluting stent (BP-SES) versus a durable coating everolimus-eluting stent (DP-EES). Material and methods We analyzed patients with AMI (STEMI and NSTEMI) treated with either a BP-SES (ALEX, Balton, Poland, n = 886) or DP-EES (XIENCE, Abbott, USA, n = 1054) with available 1-year clinical follow-up using propensity sco…

medicine.medical_specialtyEverolimus eluting stentmedicine.medical_treatmentacute myocardial infarctionlcsh:Medicine030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinemedicineIn patientcardiovascular diseases030212 general & internal medicineMyocardial infarctionOriginal Paperbusiness.industrylcsh:Rdrug-eluting stentsStentPercutaneous coronary interventionequipment and suppliesmedicine.diseaseBiodegradable polymerSurgerybioabsorbable polymerSirolimusPropensity score matchingCardiology and Cardiovascular Medicinebusinessmedicine.drugAdvances in Interventional Cardiology
researchProduct

058 THE ROLE OF FEMALE SEX IN THE CONTEMPORARY TREATMENT OF THE LEFT MAIN CORONARY ARTERY INSIGHTS FROM THE W-DELTA (WOMEN-DRUG ELUTING STENT FOR LEF…

2013

Background The optimal revascularization strategy of women with unprotected left main coronary artery (ULMCA) disease is unknown. Therefore, the aim of this study was to evaluate long-term clinical outcomes in this cohort treated with percutaneous coronary intervention (PCI) utilising drug-eluting stents (DES) versus coronary artery bypass grafting (CABG). Methods All consecutive women from the Drug Eluting stent for LefT main coronary Artery disease (DELTA) Registry with ULMCA disease treated by PCI with DES or CABG were analysed. A propensity matching was performed to adjust for baseline differences between the 2 treatment groups. Results In total, 818 women were included: 489 (59.8%) und…

medicine.medical_specialtyInterventional cardiologybusiness.industrymedicine.medical_treatmentPercutaneous coronary interventionRevascularizationmedicine.diseaseDrug-eluting stentInternal medicineConventional PCIPropensity score matchingCardiologymedicinecardiovascular diseasesMyocardial infarctionCardiology and Cardiovascular MedicinebusinessStrokeHeart
researchProduct

Drug eluting and bare metal stents in people with and without diabetes: Collaborative network meta-analysis

2008

Objective To compare the effectiveness and safety of three types of stents (sirolimus eluting, paclitaxel eluting, and bare metal) in people with and without diabetes mellitus. Design Collaborative network meta-analysis. Data sources Electronic databases (Medline, Embase, the Cochrane Central Register of Controlled Trials), relevant websites, reference lists, conference abstracts, reviews, book chapters, and proceedings of advisory panels for the US Food and Drug Administration. Manufacturers and trialists provided additional data. Review methods Network meta-analysis with a mixed treatment comparison method to combine direct within trial comparisons between stents with indirect evidence fr…

medicine.medical_specialtyPaclitaxelmedicine.medical_treatment030204 cardiovascular system & hematologyCoronary Restenosis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBlood vessel prosthesisInternal medicinemedicineHumans030212 general & internal medicinecardiovascular diseasesGeneral Environmental ScienceRandomized Controlled Trials as TopicSirolimusbusiness.industryResearchHazard ratioGeneral EngineeringDrug-Eluting StentsGeneral Medicineequipment and supplies3. Good healthSurgeryBlood Vessel ProsthesisProsthesis FailureClinical trialsurgical procedures operativePaclitaxelchemistryDrug-eluting stentMeta-analysisSirolimusGeneral Earth and Planetary SciencesPlatelet aggregation inhibitorStentsbusinessDiabetic AngiopathiesPlatelet Aggregation Inhibitorsmedicine.drug
researchProduct

Biodegradable polymer-coated thin strut sirolimus- -eluting stent versus durable polymer-coated everolimus-eluting stent in the diabetic population.

2021

Background: The number of patients with diabetes mellitus (DM) presenting with coronary artery disease is increasing and accounts for more than 30% of patients undergoing percutaneous coronary interventions (PCI). The biodegradable polymer drug-eluting stents were developed to improve vascular healing. It was sought herein, to determine 1-year clinical follow-up in patients with DM treated with the thin strut biodegradable polymer-coated sirolimus-eluting stent (BP-SES) versus durable coating everolimus-eluting stent (DP-EES). Methods: Patients were retrospectively analyzed with DM were treated with either a BP-SES (ALEX™, Balton, Poland, n = 670) or a DP-EES (XIENCE™, Abbott, USA, n = 884)…

medicine.medical_specialtyPercutaneousPolymersmedicine.medical_treatmentPopulation030204 cardiovascular system & hematologyProsthesis DesignCoronary artery disease03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionInternal medicineAbsorbable ImplantsDiabetes MellitusMedicineHumansMyocardial infarctionEverolimuseducationRetrospective StudiesSirolimuseducation.field_of_studybusiness.industryStentPercutaneous coronary interventionCardiovascular AgentsDrug-Eluting StentsGeneral Medicinemedicine.diseaseInterventional CardiologySurgeryTreatment OutcomeSirolimusConventional PCICardiologyPolandCardiology and Cardiovascular Medicinebusinessmedicine.drugCardiology journal
researchProduct

Utility of Intravascular Ultrasound in Percutaneous Revascularization of Chronic Total Occlusions

2016

Intravascular ultrasound has been used for >20 years to guide percutaneous coronary intervention in different subsets of coronary lesions. During the last decade, the interest in percutaneous coronary intervention for chronic total occlusion (CTO) has increased dramatically, leading to high success rates. Failure of guidewire crossing is the most common reason for failed CTO attempts. Certain angiographic features, such as blunt proximal CTO cap, tortuosity, heavy calcification, and lack of visibility of path in the distal vessel, increase procedural difficulty. A better understanding of the behavior of the guidewire within the CTO segment may represent a key issue to achieve successful …

medicine.medical_specialtyPercutaneousmedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentPercutaneous coronary intervention030204 cardiovascular system & hematologyRevascularizationTotal occlusionSettore MED/11 - Malattie Dell'Apparato Cardiovascolare03 medical and health sciences0302 clinical medicineBluntInternal medicineCTO = chronic total occlusion DES = drug-eluting stents IVUS = intravascular ultrasound MACE = major adverse cardiac event(s) PCI = percutaneous coronary interventionIntravascular ultrasoundConventional PCImedicineCardiology030212 general & internal medicineRadiologyCardiology and Cardiovascular MedicinebusinessMace
researchProduct

Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with …

2015

Abstract Background Third-generation drug-eluting metal stents are the gold standard for treatment of coronary artery disease. The permanent metallic caging of the vessel, however, can result in limited vasomotion, chronic inflammation, and late expansive remodeling, conditions that can lead to late and very late stent thrombosis. The development of bioresorbable scaffolds (BRSs) promises advantages over metal stents due to complete biodegradation within 2–4 years. Theoretically, since vessel scaffolding is temporary and no permanent implant remains in the vessel, BRSs, as opposed to metal stents, once degraded would no longer be potential triggers for stent-related adverse events or side e…

medicine.medical_specialtyPercutaneousmedicine.medical_treatmentMedizin030204 cardiovascular system & hematologyRevascularizationlaw.inventionCohort StudiesCoronary artery disease03 medical and health sciences0302 clinical medicineRandomized controlled triallawGermanyAbsorbable ImplantsmedicineHumansEverolimusProspective StudiesRegistries030212 general & internal medicineMyocardial infarctionEverolimusbusiness.industryCoronary StenosisPercutaneous coronary interventionDrug-Eluting StentsGeneral Medicinemedicine.diseaseSurgeryStenosisTreatment OutcomeResearch DesignAustriaCardiology and Cardiovascular Medicinebusinessmedicine.drugCardiovascular Revascularization Medicine
researchProduct

Coronary artery bypass graft versus percutaneous coronary intervention with drug-eluting stent implantation for diabetic patients with unprotected le…

2013

textabstractAims: Data regarding the impact on clinical outcomes of PCI with DES implantation vs. CABG to treat unprotected left main coronary artery (ULMCA) disease in diabetic patients are still insufficient. The present study evaluated the short-term and long-term results of percutaneous and surgical revascularisation in diabetic patients with ULMCA disease in a large population. Methods and results: A total of 826 diabetic patients with ULMCA stenosis who received DES (n=520) or underwent CABG (n=306) were selected and analysed from the DELTA registry. In-hospital MACCE was significantly higher in the CABG group, mainly driven by a higher incidence of MI. At four-year follow-up, freedom…

medicine.medical_specialtyPercutaneousmedicine.medical_treatmentMedizinCoronary Artery DiseasePercutaneous Coronary InterventionSDG 3 - Good Health and Well-beingInternal medicineDiabetes mellitusmedicineDiabetes MellitusHumanscardiovascular diseasesRegistriesCoronary Artery Bypassbusiness.industryPercutaneous coronary interventionDrug-Eluting Stentsmedicine.diseaseSurgeryStenosismedicine.anatomical_structuresurgical procedures operativeTreatment OutcomeDrug-eluting stentConcomitantConventional PCICardiologyCardiology and Cardiovascular MedicinebusinessArteryEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
researchProduct